BIVI Biovie Inc
Company Analysis
Latest News
🟢 Biovie is trading 5.4% up in pre-market as shares rebound after the September 18 decline
Biovie is trading 5.43% up at $1.69 before the September 28, 2026 session, rebounding from the September 25 close of $1.60 after several sessions near...
🟢 Biovie is trading 6.83% up today
Biovie is trading 6.83% higher at $1.72 on September 25, 2026, with no clearly reported company-specific catalyst identified for the move. - Recent coverage...
🟢 Biovie is trading 5.53% up today as broader markets rise
Biovie is trading 5.53% up at $1.70, moving higher alongside a constructive broader market. - The S&P 500, NASDAQ Composite, and Dow Jones were up 0.79%,...
🔴 Biovie is trading 5% down today after its Phase 2 ADDRESS-LC trial missed statistical significance
Biovie is trading 5% down at $1.69 after September 15 results showed its Phase 2 ADDRESS-LC trial missed statistical significance across all 22 endpoints in...
🟢 Biovie is trading 5.62% up in pre-market after broader risk sentiment improved overnight
Biovie is trading 5.62% higher at $1.88 after broader risk sentiment improved overnight. - U.S. futures are higher, with the Nasdaq Composite up 0.52%. -...
🟢 Biovie is trading 5.4% up today as U.S. stocks rally after Fed’s rate decision
Biovie is trading 5.4% up at $1.81, as U.S. stocks rally following the Federal Reserve’s September 16 rate decision. - The S&P 500 is up 0.96%, while the...
🟢 Biovie is trading 5.8% up in after-hours trading with no fresh catalyst identified
Biovie is trading at $1.82, up +5.81% in after-hours trading, rebounding after a prior decline. - Biovie declined 14.63% to $1.75 on September 15. - The Phase...
🟢 Biovie is trading 6.97% up in pre-market amid speculative volatility
Biovie is trading 6.97% up at $1.87, with the move appearing to reflect speculative volatility and broader pre-market risk appetite. - Rebounding after a...
🔴 Biovie is trading 18.05% down today after ADDRESS-LC failed on every endpoint
Biovie is trading 18.05% down at $1.68 after its 203-patient Phase 2 ADDRESS-LC trial failed to achieve statistical significance on any endpoint in the overall...
🔴 Biovie is trading 18.5% down today after Phase 2 ADDRESS-LC trial failed to reach significance
Biovie is trading at $1.68 (-18.54%) after its 203-patient Phase 2 ADDRESS-LC trial failed to achieve statistical significance on any endpoint in the overall...
Biovie's Long COVID Drug Stumbles Again — Can a Parkinson's Bright Spot Save This Tiny Biotech From Investor Fatigue?
Shares of Biovie Inc. (BIVI) cratered nearly 10% to $1.85 in pre-market trading after the company disclosed that its Phase 2 Long COVID trial failed to prove...
🔴 Biovie is trading 6.3% down in pre-market after Phase 2 ADDRESS-LC trial failed to achieve significance
Biovie is trading 6.3% down now at $1.92 after its Phase 2 ADDRESS-LC trial failed to achieve statistical significance across endpoints in the overall...
🔴 Biovie is trading 9.76% down in pre-market after Phase 2 ADDRESS-LC trial missed significance across endpoints
Biovie is trading 9.76% down at $1.85 after its Phase 2 ADDRESS-LC trial failed to achieve statistical significance across all endpoints in the overall...
🔴 Biovie is trading 5.37% down in after-hours trading after Phase 2 trial misses statistical significance
Biovie is trading at $1.94 (-5.37%) after its Phase 2 ADDRESS-LC trial failed to achieve statistical significance across all endpoints in the overall...
🟢 Biovie is trading 5% up despite broader market weakness
Biovie is trading 5.18% up at $2.03 on September 14, 2026, with no confirmed company-specific catalyst identified. - No new company-specific announcement...
🔴 Biovie is trading 5% down today — no clear company-specific announcement identified
Biovie is trading 5.07% down at $1.97, with no clear company-specific announcement identified for September 9, 2026. - Recent catalyst remains anticipation of...
🟢 Biovie is trading 6.5% up today amid anticipation of ADDRESS-LC topline results
Biovie is trading 6.5% up at $2.13, possibly supported by anticipation of ADDRESS-LC topline results targeted before September 30, 2026. - Shares rose from...
🟢 Biovie is trading 6% up in pre-market with topline results expected by September's end
Biovie is trading 6% up at $2.12, based on its pre-market price versus the September 4, 2026 close of $2.00; the gain may reflect anticipation of upcoming...
🔴 Biovie is trading 10% down today despite broader market gains
Biovie is trading 10.04% down at $2.02, extending weakness despite biotechnology and major U.S. indexes moving higher on September 2, 2026; no company-specific...
🔴 Biovie is trading 6.47% down today — no company-specific explanation identified
Biovie is trading 6.47% down now at $2.10, despite broader biotechnology strength and higher major U.S. indexes; no company-specific announcement explaining...